Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers.

ABSTRACT:

Background

Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown.

Methods

To investigate humoral immunity after COVID-19 vaccination in HTLV-1 carriers, a multicenter, prospective observational cohort study was conducted at five institutions in southwestern Japan, an endemic area for HTLV-1. HTLV-1 carriers and HTLV-1-negative controls were enrolled for this study from January to December 2022. During this period, the third dose of the COVID-19 vaccine was actively administered. HTLV-1 carriers were enrolled during outpatient visits, while HTLV-1-negative controls included health care workers and patients treated by participating institutions for diabetes, hypertens

SUBMITTER: Kameda T 

PROVIDER: S-EPMC10792913 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature